Cilo Cybin IPO and investment history

We are excited to invite you to an exclusive interactive webinar where our CEO, Gabriel Theron, provides insights on the much-anticipated 2024 Initial Public Offering (IPO). This informative session promises to be enlightening for investors, stakeholders, and anyone interested in understanding the intricacies of our company's next strategic move. Watch the full webinar below.

I am pleased to share a significant update with you. Cilo Cybin Holdings Ltd, a Special Purpose Acquisition Company (SPAC) aiming to operate at the intersection of biotechnology, pharmaceuticals, and AI technology, has received our prospectus's approval from the CIPC in South Africa.

Though our journey started slower than anticipated, we are now on track. With the backing of ALPS Global Berhard from Malaysia, who provided $3 million in funding, we are excited to announce the opening of our IPO to the public. This is a unique opportunity to invest in a company pioneering advancements in biotechnology and pharmaceuticals.

Cilo Cybin Holdings Ltd's first target company, Cilo Cybin Pharmaceutical, is one of the leading cannabis companies in South Africa that specializes in the cultivation and manufacturing of medicines under GMP in the Medical Cannabis sector. Cilo Cybin Pharmaceutical is also set to commence clinical trials on Cannabis products with ALPS Global in 2024.

ALPS (www.alps-holdings.com) and Dr Tham Seng Kong, the ALPS founder and CEO, have each invested USD1.5million in Cilo Cybin. The USD3million was converted into R54 648 279 and paid into the Cilo Cybin Escrow Account managed by FNB (“all- inclusive the “Alps Subscription”). After implementation of the offer to the public (“IPO”) as set out in more detail in the Cilo Cybin Prospectus dated 26 February 2024 (the “Prospectus”) ALPS and Dr Tham will in aggregate own 81% of the Cilo Cybin shares.

ALPS, a Malaysian based company, focus on precision medicine and preventative medicine giving a second chance by enabling accessibility and affordability to all. ALPS is a market leader in DNA – Whole Genome Sequencing that forms the basis of preventative medicine and cell therapy that include regenerative medicine, specialised cells (induced pluripotent stem cells) iPSCs and immunotherapy with a cancer treatment focus. Technologies used includes genomics DNA, mRNA, and cellular therapy.

ALPS operates and its market penetration strategy is focused on the South East Asia market, with a GDP of US$9.7 trillion that includes countries such as Singapore, Malaysia, Indonesia, Philippines, Thailand, etc. ALPS is in the process of listing on Nasdaq and have announced the take-over of a Nasdaq listed SPAC named Globalink Investment in a deal that values ALPS at US$1.6billion. The merger is expected to close in the second quarter of 2024 and the combined company will be named “Alps Life Sciences Inc”. The proceeds from the ALPS Nasdaq listing will be used to fund capex and future global growth.

The stated intention is to use Cilo Cybin as the ALPS patented biotech drugs platform.

At Cilo Cybin Holdings, our journey has been characterized by perseverance, adaptability, and a commitment to our vision. Below is a brief history of our progress: